Aseem Malhotra, MBBS
British cardiologist (MBBS); former NHS cardiology registrar/consultant roles
A prominent and outspoken critic of the lipid hypothesis who argues that the focus on LDL is misguided and that statins are over-prescribed, with insulin resistance, ultra-processed food, and lifestyle as the real drivers of heart disease. His broader public profile (including COVID-vaccine claims widely criticised as misinformation) has damaged his credibility, so his specific cholesterol claims should be weighed on their evidence rather than his standing.
Position (a lossy summary - the nuance is below)
LDL: benign to causal
-0.80 (strongly toward "LDL benign")
Argues there is no convincing population-level evidence that lowering LDL has reduced heart-disease deaths, that LDL may serve a protective immune function, and that higher LDL in the elderly is associated with longer life - a clear rejection of LDL as a primary causal target.
Statins: anti to pro
-0.90 (strongly toward "Anti-statin")
A leading public campaigner against routine statin use, arguing benefits are inflated by industry-sponsored evidence and side effects are understated; his book is titled "A Statin-Free Life".
One of the most prominent credentialed cardiologists to challenge the lipid hypothesis, emphasising insulin resistance and lifestyle. His specific points on relative-vs-absolute statin benefit overlap with serious critiques, but his framing is contested and his wider credibility is compromised.
Key arguments
- No convincing population-level evidence that statins have lowered heart-disease deaths.
- LDL may serve a protective immune function; "bad cholesterol" is reductive.
- About 80% of heart disease is lifestyle/environmental; insulin resistance is the real culprit.
Positions on specific claims
- Do statins meaningfully help people at low risk who have not had a heart event?
Argues statins are over-prescribed and of little benefit in primary prevention.
- Does metabolic health change how dangerous a given LDL level is?
Argues insulin resistance and lifestyle, not LDL, are the primary drivers.
Conflicts of interest
Book sales ("A Statin-Free Life"), paid public speaking, and a media profile built substantially on anti-statin advocacy.
Fair criticisms
- The British Heart Foundation has called his views "misleading and wrong".
- A 2017 article of his was criticised as based on cherry-picked science.
- His COVID-vaccine claims have been described by experts as misinformation, damaging his credibility.